Feds Eye Partial Pretrial Ruling In Regeneron FCA Case

By Lauren Berg · October 2, 2025, 9:48 PM EDT

The government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it...

To view the full article, register now.

Documents

Case Information

Case Title

United States of America v. Regeneron Pharmaceuticals, Inc.

Case Number

1:20-cv-11217

Court

Massachusetts

Nature of Suit

Other Statutes: False Claims Act

Date Filed

June 24, 2020